IMTX

+ Watchlist + Portfolio

Immatics N.V.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.25
52-Week Range: $5.05 – $12.41
Market Cap: $1.17B
P/E (TTM): —
EPS (TTM): -1.84
Dividend Yield: —

Advanced Metrics

Price/Book: 2.22
PEG Ratio: —
Return on Equity: -47.80%
Return on Assets: -26.92%
Gross Margin: 0.00%
Operating Margin: -734.95%
Profit Margin: 0.00%
Current Ratio: 7.54
Debt/Equity: 0.04
Total Debt: $14.61M
Free Cash Flow: $-129.10M
Revenue Growth: 93.00%
Earnings Growth: —
Enterprise Value: $877.89M

IMTX Income statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Revenue	$172.83M	$54.00M	$155.84M	$48.27M
Research & Development	$106.78M	$118.66M	$148.08M	$183.83M
Selling, General & Admin	$36.12M	$38.20M	$46.45M	$51.18M
Operating Expenses	$142.88M	$155.72M	$194.45M	$230.28M
Operating Income	$29.95M	-$101.72M	-$38.62M	-$182.02M
EBITDA	$50.04M	-$88.93M	$34.46M	-$185.09M
Pretax Income	$42.04M	-$96.99M	$21.35M	-$198.44M
Income Tax	$14.33M	-$2.35M	$6.13M	-$1.99M
Net Income	$27.70M	-$94.65M	$15.22M	-$196.45M
Diluted EPS	0.55	-1.18	0.14	-1.61
Diluted Shares	68.21M	80.55M	106.80M	122.35M

IMTX Balance Sheet statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$148.52M	$218.47M	$236.75M	$345.92M
Receivables	$1.11M	$5.74M	$6.75M	$6.88M
Current Assets	$377.15M	$449.37M	$629.55M	$504.01M
Total Assets	$407.82M	$509.96M	$696.15M	$562.34M
Current Liabilities	$106.45M	$156.55M	$67.99M	$43.01M
Total Debt	$14.56M	$15.40M	$16.20M	$15.63M
Total Liabilities	$204.47M	$292.35M	$121.30M	$78.24M
Retained Earnings	-$510.11M	-$604.76M	-$589.54M	-$785.99M
Shareholders' Equity	$203.35M	$217.62M	$574.84M	$484.10M
Working Capital	$270.70M	$292.82M	$561.57M	$461.00M

IMTX Cash Flow statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$100.13M	$18.23M	-$158.03M	-$176.63M
Capital Expenditure	-$6.21M	-$30.96M	-$16.48M	-$6.80M
Free Cash Flow	$93.92M	-$12.73M	-$174.51M	-$183.43M
Depreciation & Amortisation	$6.97M	$7.23M	$12.22M	$12.40M
Stock-Based Compensation	$22.57M	$20.70M	$17.64M	$15.02M
Investing Cash Flow	-$209.79M	-$31.39M	-$152.39M	$204.79M
Financing Cash Flow	$123.71M	$84.52M	$319.68M	$97.35M
Net Change in Cash	$14.05M	$71.36M	$9.27M	$125.51M

IMTX Income statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$18.58M	$4.74M	$5.19M	$19.76M	$7.61M
Research & Development	$41.91M	$45.11M	$47.18M	$49.64M	$59.19M
Selling, General & Admin	$12.07M	$12.78M	$12.67M	$13.66M	$14.51M
Operating Expenses	$53.96M	$57.86M	$59.82M	$58.64M	$73.68M
Operating Income	-$35.37M	-$53.13M	-$54.63M	-$38.88M	-$66.06M
EBITDA	-$37.46M	-$68.08M	-$47.38M	-$32.17M	-$54.77M
Pretax Income	-$40.85M	-$71.35M	-$50.67M	-$35.56M	-$57.76M
Income Tax	-$994.00K	-$1.00M	-$127.00K	$134.00K	$52.00K
Net Income	-$39.85M	-$70.35M	-$50.55M	-$35.70M	-$57.81M
Diluted EPS	-0.33	-0.58	-0.42	—	-0.43
Diluted Shares	121.55M	121.55M	121.56M	—	134.64M

IMTX Balance Sheet statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$242.84M	$256.63M	$334.92M	$345.92M	$301.33M
Receivables	$6.58M	$2.91M	$4.30M	$6.88M	$4.82M
Current Assets	$573.56M	$503.94M	$458.02M	$504.01M	$484.84M
Total Assets	$641.69M	$567.30M	$518.56M	$562.34M	$543.26M
Current Liabilities	$55.77M	$57.25M	$62.26M	$43.01M	$55.25M
Total Debt	$18.39M	$17.12M	$16.38M	$15.63M	$15.08M
Total Liabilities	$105.09M	$102.73M	$101.88M	$78.24M	$87.46M
Retained Earnings	-$629.40M	-$699.75M	-$750.29M	-$785.99M	-$843.80M
Shareholders' Equity	$536.61M	$464.57M	$416.68M	$484.10M	$455.80M
Working Capital	$517.79M	$446.69M	$395.76M	$461.00M	$429.59M

IMTX Cash Flow statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$34.21M	-$39.05M	-$44.70M	-$58.66M	-$42.04M
Capital Expenditure	-$3.13M	-$1.56M	-$1.08M	-$1.03M	-$763.00K
Free Cash Flow	-$37.34M	-$40.61M	-$45.78M	-$59.69M	-$42.81M
Depreciation & Amortisation	$3.14M	$3.03M	$3.06M	$3.17M	$2.77M
Stock-Based Compensation	$4.33M	$4.14M	$3.24M	$3.30M	$5.91M
Investing Cash Flow	$46.81M	$64.25M	$122.65M	-$28.92M	-$28.08M
Financing Cash Flow	-$737.00K	-$727.00K	-$734.00K	$99.55M	$20.97M
Net Change in Cash	$11.87M	$24.47M	$77.22M	$11.97M	-$49.16M

Market Snapshot

About

Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T cell receptor (TCR) based immunotherapies for cancer treatment. The company's proprietary technology platform identifies cancer-specific targets and engineers TCRs to direct patients' immune systems to detect and eliminate tumor cells. Immatics is advancing multiple TCR therapy candidates through clinical trials, targeting various solid tumors and hematological malignancies. The company combines its target discovery capabilities with adoptive cell therapy and TCR bispecifics development to create a comprehensive oncology pipeline.